Genzada Pharmaceuticals USA, Inc.

Dr. Feldman publishes extensively on the treatment of psoriasis and other dermatological ailments. He is the chief medical editor of The Dermatologist, editor of the Journal of Dermatological Treatment and writes a column for PM360 on medical adherence.

In his practice, Feldman instituted medical adherence studies that revolutionized how he and others practice dermatology. Over the past decade, Feldman has developed practical ways to improve patient medication adherence, and has published prolifically on the subject, including Practical Ways to Improve Patients’ Treatment Outcomes. His current research has expanded to improve adherence among patients taking hypertension, cholesterol, psychiatric and diabetes medications.

In his research, Feldman has demonstrated that working with industry can revolutionize how doctors practice medicine and how patients approach medications. In addition to improving patient wellness, increasing medical adherence aids many areas of industry—including health systems, pharmaceutical companies, insurance companies and others who benefit from patients using their medications.

Feldman works closely with industry in his research, consulting with companies as a psoriasis expert, participating in advisory boards, and directing both industry-initiated and investigator-initiated clinical trials. His collaboration with industry includes establishing the Center for Dermatology Research in an effort to improve dermatologic care.

Feldman earned his medical degree and doctorate from Duke University. He completed his dermatology residency at the University of North Carolina at Chapel Hill, and his dermatopathology residency at the Medical University of South Carolina. After his fellowships, Feldman joined the dermatology department of Wake Forest School of Medicine in 1991, and became director of the psoriasis treatment center in 1992.